Brigatinib
- TRADE NAME: Alunbrig (Ariad)
- INDICATIONS: Anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in patients who have progressed on, or are intolerant to, crizotinib
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 25 hours
FDA APPROVAL DATE: 04/28/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Boceprevir, Carbamazepine, Clarithromycin, Cobicistat, Conivaptan, CYP3A substrates and strong CYP3A inducers or inhibitors, Grapefruit Juice, Hormonal contraceptives, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Voriconazole
PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric